These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 26330258)

  • 1. Impact of Biomarkers on Personalized Medicine.
    Carrigan P; Krahn T
    Handb Exp Pharmacol; 2016; 232():285-311. PubMed ID: 26330258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine.
    Li M; Yu T; Hu YF
    Stat Med; 2015 Jun; 34(14):2222-34. PubMed ID: 25779099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology.
    Landeck L; Kneip C; Reischl J; Asadullah K
    Exp Dermatol; 2016 May; 25(5):333-9. PubMed ID: 27167702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research and development for cancer biomarker].
    Nakagawa H
    Nihon Rinsho; 2012 May; 70(5):743-7. PubMed ID: 22619995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics.
    Batrla R; Jordan BW
    Ann N Y Acad Sci; 2015 Jun; 1346(1):71-80. PubMed ID: 25866164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation.
    Salter H; Holland R
    J Intern Med; 2014 Sep; 276(3):215-28. PubMed ID: 24605903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
    Jørgensen JT
    Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Quantitative Assessment of Factors Affecting the Technological Development and Adoption of Companion Diagnostics.
    Luo D; Smith JA; Meadows NA; Schuh A; Manescu KE; Bure K; Davies B; Horne R; Kope M; DiGiusto DL; Brindley DA
    Front Genet; 2015; 6():357. PubMed ID: 26858745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics and Personalized Medicine.
    Koen N; Du Preez I; Loots du T
    Adv Protein Chem Struct Biol; 2016; 102():53-78. PubMed ID: 26827602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics.
    Halim AB
    Ann N Y Acad Sci; 2015 Jun; 1346(1):63-70. PubMed ID: 25758153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein array-based companion diagnostics in precision medicine.
    Poulsen TBG; Karamehmedovic A; Aboo C; Jørgensen MM; Yu X; Fang X; Blackburn JM; Nielsen CH; Kragstrup TW; Stensballe A
    Expert Rev Mol Diagn; 2020 Dec; 20(12):1183-1198. PubMed ID: 33315478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Proteomics in the Development of Personalized Medicine.
    Jain KK
    Adv Protein Chem Struct Biol; 2016; 102():41-52. PubMed ID: 26827601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
    Donovan MJ; Cordon-Cardo C
    Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation.
    Sin DD; Hollander Z; DeMarco ML; McManus BM; Ng RT
    Am J Respir Crit Care Med; 2015 Nov; 192(10):1162-70. PubMed ID: 26176936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary versus companion diagnostics: apples and oranges?
    Milne CP; Bryan C; Garafalo S; McKiernan M
    Biomark Med; 2015; 9(1):25-34. PubMed ID: 25605453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
    Sapsford KE; Tezak Z; Kondratovich M; Pacanowski MA; Zineh I; Mansfield E
    Ther Deliv; 2010 Nov; 1(5):631-41. PubMed ID: 22833953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New directions in biomarker research, drug development and personalized medicine].
    Németh G; Jelinek I
    Magy Onkol; 2013 Mar; 57(1):5-10. PubMed ID: 23573515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.